Spyre Therapeutics (SYRE) Amortizatization of Intangibles (2015 - 2026)

Spyre Therapeutics' Amortizatization of Intangibles history runs 12 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• Quarterly Amortizatization of Intangibles fell 22.07% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 million (down 35.41% YoY) and the FY2025 annual result came in at $8.1 million, down 29.06% from the prior year.
• Amortizatization of Intangibles was $2.1 million for Q1 2026 at Spyre Therapeutics, down from $2.1 million in the prior quarter.
• Across five years, Amortizatization of Intangibles topped out at $3.6 million in Q2 2024 and bottomed at -$15000.0 in Q1 2022.
• A 5-year average of $1.4 million and a median of $1.7 million in 2023 frame the typical range for Amortizatization of Intangibles.
• Annual changes were most pronounced in 2023 — Amortizatization of Intangibles slumped 57.89% — and 2024, when it surged 22156.25%.
• Spyre Therapeutics' Amortizatization of Intangibles stood at $152000.0 in 2022, then jumped by 1022.37% to $1.7 million in 2023, then surged by 41.79% to $2.4 million in 2024, then decreased by 13.81% to $2.1 million in 2025, then slipped by 1.25% to $2.1 million in 2026.
• Business Quant data shows SYRE's Amortizatization of Intangibles at $2.1 million in Q1 2026, $2.1 million in Q4 2025, and $1.3 million in Q3 2025.